Verastem (VSTM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:34
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 07/06 12:00
Hedge Funds Never Loved Verastem Inc (VSTM) More
In this article we will take a look at whether hedge funds think Verastem Inc (NASDAQ:VSTM) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on I
Insider Monkey · 06/24 03:07
Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma
Business Wire · 06/22 21:05
Verastem Oncology Highlights Presentation Of Preclinical Data Supporting Combo Of VS-6766, Defactinib In Metastatic Uveal Melanoma
Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from a study
Benzinga · 06/22 20:07
Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference
Business Wire · 05/28 12:00
Billionaire Steven Cohen Bets Big on These 3 Stocks
TipRanks · 05/19 14:47
Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?